Advances in the Pathophysiology of Thrombosis in Antiphospholipid Syndrome: Molecular Mechanisms and Signaling through Lipid Rafts

被引:21
作者
Capozzi, Antonella [1 ]
Manganelli, Valeria [1 ]
Riitano, Gloria [1 ]
Caissutti, Daniela [1 ]
Longo, Agostina [1 ]
Garofalo, Tina [1 ]
Sorice, Maurizio [1 ]
Misasi, Roberta [1 ]
机构
[1] Sapienza Univ Rome, Dept Expt Med, I-00161 Rome, Italy
关键词
APS; beta; 2-GPI; aPLs; lipid rafts; TLR4; pathways; therapeutic targets; INTERNATIONAL CONSENSUS STATEMENT; REVERSES THROMBOGENIC PROPERTIES; NEUTROPHIL EXTRACELLULAR TRAPS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ENDOTHELIAL-CELL ACTIVATION; HIGH-DENSITY-LIPOPROTEIN; TISSUE FACTOR EXPRESSION; TOLL-LIKE RECEPTORS; BETA(2)-GLYCOPROTEIN I; ANNEXIN A2;
D O I
10.3390/jcm12030891
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The pathological features of antiphospholipid syndrome (APS) are related to the activity of circulating antiphospholipid antibodies (aPLs) associated with vascular thrombosis and obstetric complications. Indeed, aPLs are not only disease markers, but also play a determining pathogenetic role in APS and exert their effects through the activation of cells and coagulation factors and inflammatory mediators for the materialization of the thromboinflammatory pathogenetic mechanism. Cellular activation in APS necessarily involves the interaction of aPLs with target receptors on the cell membrane, capable of triggering the signal transduction pathway(s). This interaction occurs at specific microdomains of the cell plasma membrane called lipid rafts. In this review, we focus on the key role of lipid rafts as signaling platforms in the pathogenesis of APS, and propose this pathogenetic step as a strategic target of new therapies in order to improve classical anti-thrombotic approaches with "new " immunomodulatory drugs.
引用
收藏
页数:16
相关论文
共 142 条
[1]   Antiphospholipid Syndrome and Pregnancy Pathogenesis to Translation [J].
Abrahams, Vikki M. ;
Chamley, Lawrence W. ;
Salmon, Jane E. .
ARTHRITIS & RHEUMATOLOGY, 2017, 69 (09) :1710-1721
[2]   In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions [J].
Agostinis, Chiara ;
Biffi, Stefania ;
Garrovo, Chiara ;
Durigutto, Paolo ;
Lorenzon, Andrea ;
Bek, Alpan ;
Bulla, Roberta ;
Grossi, Claudia ;
Borghi, Maria O. ;
Meroni, PierLuigi ;
Tedesco, Francesco .
BLOOD, 2011, 118 (15) :4231-4238
[3]  
ALARCONSEGOVIA D, 1989, J RHEUMATOL, V16, P762
[4]   Mitochondria-associated ER membranes (MAMs) and lysosomal storage diseases [J].
Annunziata, Ida ;
Sano, Renata ;
d'Azzo, Alessandra .
CELL DEATH & DISEASE, 2018, 9
[5]   Use of New Oral Anticoagulants in Antiphospholipid Syndrome [J].
Arachchillage, Deepa Jayakody ;
Cohen, Hannah .
CURRENT RHEUMATOLOGY REPORTS, 2013, 15 (06)
[6]   β2-glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model [J].
Arad, Ariela ;
Proulle, Valerie ;
Furie, Richard A. ;
Furie, Barbara C. ;
Furie, Bruce .
BLOOD, 2011, 117 (12) :3453-3459
[7]   Phosphorylation and stabilization of ATP binding cassette transporter a1 by synthetic Amphiphilic helical peptides [J].
Arakawa, R ;
Hayashi, M ;
Remaley, AT ;
Brewer, BH ;
Yamauchi, Y ;
Yokoyama, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (08) :6217-6220
[8]   The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment [J].
Asherson, RA .
LUPUS, 1998, 7 :S55-S62
[9]   Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines [J].
Asherson, RA ;
Cervera, R ;
de Groot, PG ;
Erkan, D ;
Boffa, MC ;
Piette, JC ;
Khamashta, MA ;
Shoenfeld, Y .
LUPUS, 2003, 12 (07) :530-534
[10]   Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow [J].
Bafico, A ;
Liu, GZ ;
Yaniv, A ;
Gazit, A ;
Aaronson, SA .
NATURE CELL BIOLOGY, 2001, 3 (07) :683-686